LA JOLLA PHARMACEUTICAL CO Research and Development Expense (Excluding Acquired in Process Cost)
LA JOLLA PHARMACEUTICAL CO reported Research and Development Expense (Excluding Acquired in Process Cost) of $700.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2019-03-04
- LA JOLLA PHARMACEUTICAL CO research and development expense (excluding acquired in process cost) for fiscal 2018 was $700.00K, a 56.25% decline from fiscal 2017.
- LA JOLLA PHARMACEUTICAL CO research and development expense (excluding acquired in process cost) for fiscal 2017 was $1.60M, a 220.00% increase from fiscal 2016.
- LA JOLLA PHARMACEUTICAL CO research and development expense (excluding acquired in process cost) for fiscal 2016 was $500.00K.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|
| 2018-12-31 | $700.00K 10-K · filed 2019-03-04 |
| 2017-12-31 | $1.60M 10-K · filed 2019-03-04 |
| 2016-12-31 | $500.00K 10-K · filed 2019-03-04 |